Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | FASN | P49327 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902595 | 0.86 | DGAT1 (0.61) | MAP4K1DGAT1KCNH2ADORA2A | |
| SCHEMBL902783 | 0.75 | DGAT1 (0.45) | MAP4K1DGAT1KCNH2FASNADORA2A | |
| SCHEMBL902660 | 0.74 | DGAT1 (0.44) | DGAT1KCNH2GSK3BADORA2A | |
| SCHEMBL902778 | 0.66 | DGAT1 (0.64) | DGAT1KCNH2ADORA2A | |
| SCHEMBL902755 | 0.66 | DGAT1 (0.70) | DGAT1KCNH2ADORA2A | |
| SCHEMBL901853 | 0.66 | DGAT1 (0.70) | DGAT1KCNH2ADORA2A | |
| SCHEMBL31289497 | 0.66 | MEN1 (0.52) | — | |
| SCHEMBL902489 | 0.66 | ATR (0.47) | DGAT1 | |
| SCHEMBL10189107 | 0.66 | DGAT1 (0.86) | DGAT1KCNH2ADORA2A | |
| SCHEMBL902382 | 0.66 | DGAT1 (0.72) | DGAT1KCNH2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |